Albert Jang
Overview
Explore the profile of Albert Jang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
739
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Liao R, Ruan H, Jang A, Huynh M, Nadal Rios R, Hoffman-Censits J, et al.
Am Soc Clin Oncol Educ Book
. 2024 Jan;
44:e430336.
PMID: 38176691
Small-cell carcinomas (SCCs) of the genitourinary (GU) tract are rare malignancies with high metastatic potential. The most common primary sites are the bladder and prostate, but case reports of primary...
12.
Jang A, Lanka S, Ruan H, Kumar H, Jia A, Garcia J, et al.
Expert Rev Anticancer Ther
. 2023 Nov;
23(12):1251-1263.
PMID: 38030394
Introduction: Patients with metastatic prostate cancer, especially in the castrate-resistant setting, have a poor prognosis. Many agents have been approved for metastatic prostate cancer, such as androgen receptor pathway inhibitors,...
13.
Jang A, Lichterman J, Zhong J, Shoag J, Garcia J, Zhang T, et al.
Hum Vaccin Immunother
. 2023 Nov;
19(3):2276629.
PMID: 37947202
Renal cell carcinoma (RCC), especially clear cell RCC, is generally considered an immunotherapy-responsive cancer. Recently, the prognosis for patients with locally advanced and metastatic RCC has significantly improved with the...
14.
Sartor O, Ledet E, Huang M, Schwartz J, Lieberman A, Lewis B, et al.
J Nucl Med
. 2023 Sep;
64(11):1721-1725.
PMID: 37770113
Lu-PSMA-617 and Lu-PSMA I&T (collectively termed Lu-PSMA) are currently being used for the treatment of selected metastatic castration-resistant prostate cancer (mCRPC) patients with PSMA PET-positive disease, but biomarkers for these...
15.
Hwang C, Henderson N, Chu S, Holland B, Cackowski F, Pilling A, et al.
JAMA Netw Open
. 2023 Sep;
6(9):e2334208.
PMID: 37721753
Importance: Black men have higher incidence and mortality from prostate cancer. Whether precision oncology disparities affect Black men with metastatic castration-resistant prostate cancer (mCRPC) is unknown. Objective: To compare precision...
16.
Jang A, Sella A, Nassar A, Koshkin V
Front Oncol
. 2023 Sep;
13:1274264.
PMID: 37692849
No abstract available.
17.
Sartor O, Jang A, Ledet E
Oncologist
. 2023 Aug;
28(11):e1127-e1128.
PMID: 37589230
No abstract available.
18.
Bian W, Jang A, Liu F
ArXiv
. 2023 Aug;
PMID: 37547657
This paper proposes a novel self-supervised learning method, RELAX-MORE, for quantitative MRI (qMRI) reconstruction. The proposed method uses an optimization algorithm to unroll a model-based qMRI reconstruction into a deep...
19.
Jang A, Kendi A, Johnson G, Halfdanarson T, Sartor O
Int J Mol Sci
. 2023 Jul;
24(14).
PMID: 37511386
Radiopharmaceuticals are rapidly developing as a field, with the successful use of targeted beta emitters in neuroendocrine tumors and prostate cancer serving as catalysts. Targeted alpha emitters are in current...
20.
Jang A, Lanka S, Jaeger E, Lieberman A, Huang M, Sartor A, et al.
JCO Precis Oncol
. 2023 Jul;
7:e2300131.
PMID: 37467457
Purpose: Circulating tumor DNA (ctDNA) detection in blood has emerged as a prognostic and predictive biomarker demonstrating improved assessment of treatment response in patients receiving immune checkpoint inhibitors (ICIs). Here,...